CT Online Desk:

The World Health Organization has urged countries in the South-East Asia region including Bangladesh to strengthen surveillance and for people to take protective measures in view of the increasing numbers of cases of respiratory diseases, including due to Covid-19 and its new sub-variant JN1, and influenza. “The Covid-19 virus continues to evolve, change, and circulate in all countries globally.  While current evidence suggests the additional public health risk posed by JN1 is low, we must continue to track the evolution of these viruses to tailor our response. For this, countries must strengthen surveillance and sequencing, and ensure sharing of data,” said Dr Poonam Khetrapal Singh, Regional Director, WHO South-East Asia. WHO has classified JN1 as a variant of interest following its rapid global spread.  In recent weeks, JN1 was reported in multiple countries, and its prevalence has been rapidly increasing globally.  Considering the available, yet limited evidence, the additional public health risk posed by JN1 is currently evaluated as low at the global level. However, Bangladesh did not get any JN1 variety yet in its routine surveillance. "Our surveillance for Covid-19 is going on. We did not find any case of JN1 variant," Prof Dr Tahmina Shirin, Director of the government's Institute of Epidemiology Disease Control and Research (IEDCR), told Dhaka Tribune. Even the number of new Covid-19 cases is insignificant, she said. WHO says it is anticipated that this variant may cause an increase in Covid-19 cases amid a surge of infections of other viral and bacterial infections, especially in countries entering the winter season. “As people travel and gather for festivities during the holiday season, spending a lot of time together indoors where poor ventilation facilitates transmission of viruses that cause respiratory diseases, they must take protective measures and seek timely clinical care when unwell,” said Dr Khetrapal Singh. The regional director also emphasized on the importance of vaccination against Covid-19 and influenza, especially for people at high risk.  “All WHO-approved Covid-19 vaccines continue to protect against severe disease and death from all variants including JN1,” she said. In May this year, following sustained decline in the trajectory of Covid-19 cases, hospitalizations and deaths, and high levels of population immunity to SARS-CoV2, WHO declared Covid-19 no longer constituted a public health emergency of international concern. While considerable progress has been made in establishing and strengthening a global system to detect and rapidly assess risks posed by SARS-CoV-2, testing and reporting of Covid-19 cases has decreased. With Covid-19 continuing to circulate at high levels globally, countries must strengthen surveillance, sequencing, and reporting to effectively manage respiratory diseases and to protect people’s health, the Regional Director said.

DCT/OL/AH/END